{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:44:48Z","timestamp":1790775888814,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["20K08009"],"award-info":[{"award-number":["20K08009"]}]},{"name":"JSPS KAKENHI","award":["20K08009"],"award-info":[{"award-number":["20K08009"]}]},{"name":"Health Sciences Research Grants for the Grant-in-aid for Cancer Research","award":["H23-009"],"award-info":[{"award-number":["H23-009"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP16ck0106093"],"award-info":[{"award-number":["JP16ck0106093"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Center Research and Development Funds","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>JCOG1015A1 is an ancillary research study to determine the organ-specific dose constraints in head and neck carcinoma treated with intensity-modulated radiation therapy (IMRT) using data from JCOG1015.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Individual patient data and dose-volume histograms of organs at risk (OAR) were collected from 74 patients with nasopharyngeal carcinoma treated with IMRT who enrolled in JCOG1015. The incidence of late toxicities was evaluated using the cumulative incidence method or prevalence proportion. ROC analysis was used to estimate the optimal DVH cut-off value that predicted toxicities.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 5-year cumulative incidences of Grade (G) 1 myelitis,\u2009\u2265\u2009G1 central nervous system (CNS) necrosis, G2 optic nerve disorder,\u2009\u2265\u2009G2 dysphagia,\u2009\u2265\u2009G2 laryngeal edema,\u2009\u2265\u2009G2 hearing impaired,\u2009\u2265\u2009G2 middle ear inflammation, and\u2009\u2265\u2009G1 hypothyroidism were 10%, 5%, 2%, 11%, 5%, 26%, 34%, and 34%, respectively. Significant associations between DVH parameters and incidences of toxicities were observed in the brainstem for myelitis (D1cc\u2009\u2265\u200955.8\u00a0Gy), in the brain for CNS necrosis (D1cc\u2009\u2265\u200972.1\u00a0Gy), in the eyeball for optic nerve disorder (Dmax\u2009\u2265\u200936.6\u00a0Gy), and in the ipsilateral inner ear for hearing impaired (Dmean\u2009\u2265\u200944\u00a0Gy). The optic nerve, pharyngeal constrictor muscle (PCM), and thyroid showed tendencies between DVH parameters and toxicity incidence. The prevalence proportion of G2 xerostomia at 2\u00a0years was 17 versus 6% (contralateral parotid gland Dmean\u2009\u2265\u200925.8\u00a0Gy vs less).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The dose constraint criteria were appropriate for most OAR in this study, although more strict dose constraints might be necessary for the inner ear, PCM, and brainstem.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02105-3","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T11:03:46Z","timestamp":1659006226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Organs-at-risk dose constraints in head and neck intensity-modulated radiation therapy using a dataset from a multi-institutional clinical trial (JCOG1015A1)"],"prefix":"10.1186","volume":"17","author":[{"given":"Masahiro","family":"Inada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumasa","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ishikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kodaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruki","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Toshiyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Minemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"2105_CR1","unstructured":"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf. Accessed 9 Sep 2021."},{"issue":"11","key":"2105_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.oraloncology.2015.08.005","volume":"51","author":"B Zhang","year":"2015","unstructured":"Zhang B, Mo Z, Wei D, Wang Y, Liu L, Wei Y. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis. Oral Oncol. 2015;51(11):1041\u20136. https:\/\/doi.org\/10.1016\/j.oraloncology.2015.08.005.","journal-title":"Oral Oncol"},{"key":"2105_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.adro.2017.05.002","volume":"2","author":"E Abel","year":"2017","unstructured":"Abel E, Silander E, Nyman J, Bove M, Johansson L, Bj\u00f6rk-Eriksson T, et al. Impact on quality of life of IMRT versus 3-D conformal radiation therapy in head and neck cancer patients: a case control study. Adv Radiat Oncol. 2017;2:346\u201353.","journal-title":"Adv Radiat Oncol"},{"key":"2105_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00066-020-01737-2","volume":"197","author":"S Tribius","year":"2021","unstructured":"Tribius S, Haladyn S, Hanken H, Busch CJ, Kr\u00fcll A, Petersen C, et al. Parotid sparing and quality of life in long-term survivors of locally advanced head and neck cancer after intensity-modulated radiation therapy. Strahlenther Onkol. 2021;197:219\u201330.","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"2105_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.radonc.2012.08.013","volume":"104","author":"G Peng","year":"2012","unstructured":"Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012;104(3):286\u201393. https:\/\/doi.org\/10.1016\/j.radonc.2012.08.013.","journal-title":"Radiother Oncol"},{"key":"2105_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015951","volume":"98","author":"MS Luo","year":"2019","unstructured":"Luo MS, Huang GJ, Liu HB. Oncologic outcomes of IMRT versus CRT for nasopharyngeal carcinoma: a meta-analysis. Medicine (Baltimore). 2019;98: e15951.","journal-title":"Medicine (Baltimore)"},{"issue":"3 Suppl","key":"2105_CR7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","volume":"76","author":"SM Bentzen","year":"2010","unstructured":"Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-9.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 Suppl","key":"2105_CR8","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","volume":"76","author":"LB Marks","year":"2010","unstructured":"Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2105_CR9","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1007\/s10147-020-01665-2","volume":"25","author":"Y Nishimura","year":"2020","unstructured":"Nishimura Y, Ishikura S, Shibata T, Kodaira T, Ito Y, Tsuchiya K, et al. A phase II study of adaptive two-step intensity-modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (JCOG1015). Int J Clin Oncol. 2020;25:1250\u20139.","journal-title":"Int J Clin Oncol"},{"key":"2105_CR10","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) [Internet]. Cancer Therapy Evaluation Program (CTEP). Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.html. Accessed 21 Dec 2021."},{"key":"2105_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamaoto.2019.3550","volume":"146","author":"A Schuette","year":"2020","unstructured":"Schuette A, Lander DP, Kallogjeri D, Collopy C, Goddu S, Wildes TM, et al. Predicting hearing loss after radiotherapy and cisplatin chemotherapy in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2020;146:106\u201312.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2105_CR12","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.ijrobp.2007.01.042","volume":"68","author":"CL Zuur","year":"2007","unstructured":"Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Rasch CR, Schornagel JH, et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys. 2007;68:1320\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2105_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1001\/jamaoto.2015.1515","volume":"141","author":"EA Theunissen","year":"2015","unstructured":"Theunissen EA, Zuur CL, J\u00f3zwiak K, Lopez-Yurda M, Hauptmann M, Rasch CR, et al. Prediction of hearing loss due to cisplatin chemoradiotherapy. JAMA Otolaryngol Head Neck Surg. 2015;141:810\u20135.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2105_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejmp.2019.04.003","volume":"61","author":"MA Mosleh-Shirazi","year":"2019","unstructured":"Mosleh-Shirazi MA, Amraee A, Mohaghegh F. Dose-response relationship and normal-tissue complication probability of conductive hearing loss in patients undergoing head-and-neck or cranial radiotherapy: a prospective study including 70 ears. Phys Med. 2019;61:64\u20139.","journal-title":"Phys Med"},{"key":"2105_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ijrobp.2019.06.2540","volume":"105","author":"AW Lee","year":"2019","unstructured":"Lee AW, Ng WT, Pan JJ, Chiang CL, Poh SS, Choi HC, et al. International guideline on dose prioritization and acceptance criteria in radiation therapy planning for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2019;105:567\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2105_CR16","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1097\/MLG.0b013e31818208d6","volume":"118","author":"YD Xu","year":"2008","unstructured":"Xu YD, Ou YK, Zheng YQ, Chen Y, Ji SF. The treatment for postirradiation otitis media with effusion: a study of three methods. Laryngoscope. 2008;118:2040\u20133.","journal-title":"Laryngoscope"},{"key":"2105_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00405-015-3518-8","volume":"273","author":"CH Hsin","year":"2016","unstructured":"Hsin CH, Tseng HC, Lin HP, Chen TH. Post-irradiation otitis media, rhinosinusitis, and their interrelationship in nasopharyngeal carcinoma patients treated by IMRT. Eur Arch Otorhinolaryngol. 2016;273:471\u20137.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2105_CR18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.radonc.2009.09.013","volume":"93","author":"SZ Wang","year":"2009","unstructured":"Wang SZ, Li J, Miyamoto CT, Chen F, Zhou LF, Zhang HY, et al. A study of middle ear function in the treatment of nasopharyngeal carcinoma with IMRT technique. Radiother Oncol. 2009;93:530\u20133.","journal-title":"Radiother Oncol"},{"key":"2105_CR19","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.ijrobp.2011.10.052","volume":"83","author":"D Pak","year":"2012","unstructured":"Pak D, Vineberg K, Feng F, Ten Haken RK, Eisbruch A. Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms. Int J Radiat Oncol Biol Phys. 2012;83:1528\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2105_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13014-018-1105-z","volume":"13","author":"CY Yao","year":"2018","unstructured":"Yao CY, Zhou GR, Wang LJ, Xu JH, Ye JJ, Zhang LF, et al. A retrospective dosimetry study of intensity-modulated radiotherapy for nasopharyngeal carcinoma: radiation-induced brainstem injury and dose-volume analysis. Radiat Oncol. 2018;13:194.","journal-title":"Radiat Oncol"},{"key":"2105_CR21","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","volume":"31","author":"AA Forastiere","year":"2013","unstructured":"Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91\u201311: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31:845\u201352.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2105_CR22","doi-asserted-by":"publisher","first-page":"E1026","DOI":"10.1002\/hed.24150","volume":"38","author":"TL Huang","year":"2016","unstructured":"Huang TL, Chien CY, Tsai WL, Liao KC, Chou SY, Lin HC, et al. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy. Head Neck. 2016;38(Suppl 1):E1026\u201332.","journal-title":"Head Neck"},{"key":"2105_CR23","doi-asserted-by":"publisher","first-page":"16396","DOI":"10.1038\/s41598-018-34803-y","volume":"8","author":"L Jiang","year":"2018","unstructured":"Jiang L, Huang C, Gan Y, Wu T, Tang X, Wang Y, et al. Radiation-induced late dysphagia after intensity-modulated radiotherapy in nasopharyngeal carcinoma patients: a dose-volume effect analysis. Sci Rep. 2018;8:16396.","journal-title":"Sci Rep"},{"key":"2105_CR24","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00066-019-01572-0","volume":"196","author":"S Mogadas","year":"2020","unstructured":"Mogadas S, Busch CJ, Pflug C, Hanken H, Kr\u00fcll A, Petersen C, et al. Influence of radiation dose to pharyngeal constrictor muscles on late dysphagia and quality of life in patients with locally advanced oropharyngeal carcinoma. Strahlenther Onkol. 2020;196:522\u20139.","journal-title":"Strahlenther Onkol"},{"key":"2105_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.rpor.2019.09.012","volume":"24","author":"RA Kannan","year":"2019","unstructured":"Kannan RA, Arul Ponni TR. Dose to swallowing structures and dysphagia in head and neck Intensity modulated radiation therapy - a long term prospective analysis. Rep Pract Oncol Radiother. 2019;24:654\u20139.","journal-title":"Rep Pract Oncol Radiother"},{"key":"2105_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/jjco\/hyt235","volume":"44","author":"MY Kim","year":"2014","unstructured":"Kim MY, Yu T, Wu HG. Dose-volumetric parameters for predicting hypothyroidism after radiotherapy for head and neck cancer. Jpn J Clin Oncol. 2014;44:331\u20137.","journal-title":"Jpn J Clin Oncol"},{"key":"2105_CR27","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/j.clon.2016.05.004","volume":"28","author":"V Lee","year":"2016","unstructured":"Lee V, Chan SY, Choi CW, Kwong D, Lam KO, Tong CC, et al. Dosimetric predictors of hypothyroidism after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma. Clin Oncol (R Coll Radiol). 2016;28:e52-60.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2105_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13014-014-0269-4","volume":"9","author":"A Chyan","year":"2014","unstructured":"Chyan A, Chen J, Shugard E, Lambert L, Quivey JM, Yom SS. Dosimetric predictors of hypothyroidism in oropharyngeal cancer patients treated with intensity-modulated radiation therapy. Radiat Oncol. 2014;9:269.","journal-title":"Radiat Oncol"},{"key":"2105_CR29","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1002\/cncr.26186","volume":"117","author":"IR Vogelius","year":"2011","unstructured":"Vogelius IR, Bentzen SM, Maraldo MV, Petersen PM, Specht L. Risk factors for radiation-induced hypothyroidism: a literature-based meta-analysis. Cancer. 2011;117:5250\u201360.","journal-title":"Cancer"},{"key":"2105_CR30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13014-020-01490-x","volume":"15","author":"L Zhou","year":"2020","unstructured":"Zhou L, Chen J, Shen W, Chen ZL, Huang S, Tao CJ, et al. Thyroid V50 is a risk factor for hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a retrospective study. Radiat Oncol. 2020;15:68.","journal-title":"Radiat Oncol"},{"key":"2105_CR31","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ijrobp.2017.03.007","volume":"98","author":"K Sommat","year":"2017","unstructured":"Sommat K, Ong WS, Hussain A, Soong YL, Tan T, Wee J, et al. Thyroid V40 predicts primary hypothyroidism after intensity modulated radiation therapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2017;98:574\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2105_CR32","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ijrobp.2006.06.013","volume":"66","author":"EH Pow","year":"2006","unstructured":"Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66(4):981\u201391. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.06.013.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2105_CR33","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1200\/JCO.2007.11.5501","volume":"25","author":"MK Kam","year":"2007","unstructured":"Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25:4873\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2105_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","volume":"12","author":"CM Nutting","year":"2011","unstructured":"Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12(2):127\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(10)70290-4.","journal-title":"Lancet Oncol"},{"key":"2105_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13014-020-01666-5","volume":"15","author":"T Gupta","year":"2020","unstructured":"Gupta T, Sinha S, Ghosh-Laskar S, Budrukkar A, Mummudi N, Swain M, et al. Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial. Radiat Oncol. 2020;15:218.","journal-title":"Radiat Oncol"},{"key":"2105_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.radonc.2012.11.005","volume":"106","author":"T Nishi","year":"2013","unstructured":"Nishi T, Nishimura Y, Shibata T, Tamura T, Nishigaito N, Okumura M. Volume and dosimetric changes and initial clinical experience of a two-step adaptive intensity modulated radiation therapy (IMRT) scheme for head and neck cancer. Radiother Oncol. 2013;106:85\u20139.","journal-title":"Radiother Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02105-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02105-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02105-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T23:08:00Z","timestamp":1659049680000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02105-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2105"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02105-3","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"22 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of the National Cancer Center (2020-468) on 16 February 2021. All patients provided written informed consent for including to JCOG1015 and for secondary use of data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}